HealthQuill AZP-3601
Eneboparatide (AZP-3601) meets its primary goal in the CALYPSO Phase III trial, offering hope for chronic hypoparathyroidism patients.
Drugs

Eneboparatide succeeds in Phase III trial for chronic hypoparathyroidism

HQ Team March 17, 2025: The Phase III CALYPSO trial, led by Alexion, AstraZeneca Rare Disease, has shown promising results for eneboparatide (AZP-3601),.

Read More